On May 18, 2026, Maryland's State Affordability Board announced a price cap on the diabetes medication Ozempic. This decision reflects ongoing efforts to address prescription drug costs.
Maryland is among nine states currently considering the implementation of prescription drug affordability boards, aiming to regulate drug prices more effectively.
The establishment of this price cap may influence discussions in other states as they evaluate strategies to manage rising medication costs.